Megan Bacon
Conference Call Host
Replay available
Avalo Therapeutics, Inc. (NASDAQ: AVTX) Q3 2024 earnings conference call, held 2024-10-30. Replay captured from the company's public earnings webcast.

Conference Call Host
Chairman and Chief Executive Officer
Chief Operating Officer and Chief Investment Officer
President
Chief Financial Officer
Analyst/Questioner (UBS)
Analyst/Questioner (B. Reilly Securities)
Analyst/Questioner (Leidenberg Thelman)
Analyst/Questioner (KBW)
Greetings and welcome to the Horizon Technology Finance Corporation third quarter 2024 earnings call. At this time, all participants are in listen only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star one or star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Megan Bacon. Thank you. You may begin. Thank you, and welcome to Horizon Technology Finance Corporation's third quarter 2024 conference call. Representing the company today are Rob Pomeroy, Chairman and Chief Executive Officer, Jerry Michaud, President, Dan Dvoracic, Chief Operating Officer and Chief Investment Officer, and Dan Trollio, Chief Financial Officer. I would like to point out that the Q3 earnings press release and Form 10-Q are are available on the company's website at horizontechfinance.com. Before we begin our formal remarks, I remind everyone that during this conference call, the company will make certain forward-looking statements, including statements with regard to the future performance of the company. Words such as believes, expects, anticipates, intends, or similar expressions are used to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ on a material basis from those projected in these forward-looking statements. And some of these factors are detailed in the risk factor discussion in the company's filings with the Securities and Exchange Commission, including the company's Form 10-K for the year ended December 31, 2023. The company undertakes no obligation to update or revise an...